IN2012DN03337A - - Google Patents
Info
- Publication number
- IN2012DN03337A IN2012DN03337A IN3337DEN2012A IN2012DN03337A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A IN 3337DEN2012 A IN3337DEN2012 A IN 3337DEN2012A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- well
- pharmaceutically acceptable
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein R1 ,R2, R3 , Ca and Cb have the significance given in claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09173178 | 2009-10-15 | ||
PCT/EP2010/065232 WO2011045292A1 (en) | 2009-10-15 | 2010-10-12 | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03337A true IN2012DN03337A (en) | 2015-10-23 |
Family
ID=43093680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3337DEN2012 IN2012DN03337A (en) | 2009-10-15 | 2010-10-12 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8440710B2 (en) |
EP (1) | EP2488493B1 (en) |
JP (1) | JP5749272B2 (en) |
KR (1) | KR101576328B1 (en) |
CN (1) | CN102858743B (en) |
AR (1) | AR078619A1 (en) |
AU (1) | AU2010305859A1 (en) |
BR (1) | BR112012008962A2 (en) |
CA (1) | CA2776457A1 (en) |
CL (1) | CL2012000937A1 (en) |
ES (1) | ES2538005T3 (en) |
HK (1) | HK1179957A1 (en) |
IL (1) | IL218958A0 (en) |
IN (1) | IN2012DN03337A (en) |
MX (1) | MX2012004311A (en) |
PE (1) | PE20121732A1 (en) |
RU (1) | RU2607080C2 (en) |
TW (1) | TW201118068A (en) |
WO (1) | WO2011045292A1 (en) |
ZA (1) | ZA201202613B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201190138A1 (en) | 2009-03-23 | 2013-05-30 | Гленмарк Фармасьютикалс, С.А. | FUROPYRIMIDINDION DERIVATIVES AS TRPA1 MODULATORS |
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
CN103319395B (en) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | Industrialization preparation method for 4-fluoroisatin and product thereby |
WO2015103756A1 (en) | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
UY36060A (en) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | AZOL COMPOUNDS REPLACED WITH AMIDA |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
JP7264906B2 (en) | 2017-11-01 | 2023-04-25 | ブリストル-マイヤーズ スクイブ カンパニー | Alkene compounds as farnesoid X receptor modulators |
CN111630051B (en) | 2017-11-01 | 2023-12-26 | 百时美施贵宝公司 | Olefin spiro compounds as farnesol X receptor modulators |
MX2020004400A (en) | 2017-11-01 | 2020-08-06 | Bristol Myers Squibb Co | Spirocyclic compounds as farnesoid x receptor modulators. |
EP3704107B1 (en) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
CN109369354B (en) * | 2018-12-15 | 2021-07-09 | 浦拉司科技(上海)有限责任公司 | Synthesis method of 4,4, 4-trifluorobutanol |
AR118050A1 (en) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | BICYCLIC COMPOUNDS REPLACED AS MODULATORS OF THE FARNESOID X RECEIVER |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10247680B4 (en) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | New bicyclic inhibitors of the hormone sensitive lipase |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
US20070135457A1 (en) | 2003-12-16 | 2007-06-14 | Pfizer Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors |
FR2870538B1 (en) * | 2004-05-19 | 2006-07-14 | Servier Lab | NOVEL DERIVATIVES OF PYRROLIDINES AND THIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
CA2648019C (en) * | 2006-04-25 | 2014-04-01 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
DK2021337T3 (en) * | 2006-04-25 | 2010-03-29 | Lilly Co Eli | Inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en active Application Filing
- 2010-10-12 TW TW099134747A patent/TW201118068A/en unknown
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/en not_active Application Discontinuation
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/en not_active IP Right Cessation
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/en not_active Expired - Fee Related
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/en active IP Right Grant
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/en not_active IP Right Cessation
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/en not_active Expired - Fee Related
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/en active Active
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/en not_active IP Right Cessation
- 2010-10-13 AR ARP100103732A patent/AR078619A1/en unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/en unknown
-
2013
- 2013-06-19 HK HK13107152.4A patent/HK1179957A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201118068A (en) | 2011-06-01 |
ES2538005T3 (en) | 2015-06-16 |
AR078619A1 (en) | 2011-11-23 |
CA2776457A1 (en) | 2011-04-21 |
CN102858743A (en) | 2013-01-02 |
IL218958A0 (en) | 2012-06-28 |
BR112012008962A2 (en) | 2019-09-24 |
AU2010305859A1 (en) | 2012-06-07 |
EP2488493A1 (en) | 2012-08-22 |
RU2012119706A (en) | 2013-11-20 |
CN102858743B (en) | 2015-06-10 |
HK1179957A1 (en) | 2013-10-11 |
KR101576328B1 (en) | 2015-12-10 |
ZA201202613B (en) | 2013-01-30 |
KR20120074304A (en) | 2012-07-05 |
JP5749272B2 (en) | 2015-07-15 |
CL2012000937A1 (en) | 2012-09-14 |
US8440710B2 (en) | 2013-05-14 |
WO2011045292A1 (en) | 2011-04-21 |
RU2607080C2 (en) | 2017-01-10 |
MX2012004311A (en) | 2012-04-30 |
JP2013507421A (en) | 2013-03-04 |
PE20121732A1 (en) | 2012-12-28 |
EP2488493B1 (en) | 2015-04-15 |
US20110092512A1 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03337A (en) | ||
MX2010005824A (en) | Aminothiazole derivatives. | |
TW200738241A (en) | Pyridazine derivatives | |
MY138941A (en) | Aryl-pyridine derivatives | |
SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
MX2011012017A (en) | Azacyclic spiroderivatives as hsl inhibitors. | |
TW200616976A (en) | Pyrimidine derivatives | |
UA108105C2 (en) | Nitrogen-containing heteroaryl compounds | |
IN2012DN01232A (en) | ||
MX2012000414A (en) | Pyridin-4-yl derivatives. | |
MX2009003939A (en) | Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes. | |
IN2012DN01233A (en) | ||
TW200740764A (en) | Pyrazolone derivatives | |
MY153921A (en) | Aminopyrazole derivatives | |
TW200616958A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
UA109037C2 (en) | Triazolepyridins | |
MX2010005714A (en) | Pyridine compounds. | |
MX2008016426A (en) | Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1). | |
UA102310C2 (en) | Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions | |
IN2012DN00765A (en) | ||
MX2009013501A (en) | Piperidine compounds and uses thereof. | |
MX2011008360A (en) | Heteroaryl substituted pyridazinone derivatives. | |
MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
MX2009003169A (en) | Sulfonamide derivatives. |